EA201390844A1 - COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION - Google Patents

COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION

Info

Publication number
EA201390844A1
EA201390844A1 EA201390844A EA201390844A EA201390844A1 EA 201390844 A1 EA201390844 A1 EA 201390844A1 EA 201390844 A EA201390844 A EA 201390844A EA 201390844 A EA201390844 A EA 201390844A EA 201390844 A1 EA201390844 A1 EA 201390844A1
Authority
EA
Eurasian Patent Office
Prior art keywords
valsartan
lercanidipine hydrochloride
preparation
composition containing
complex composition
Prior art date
Application number
EA201390844A
Other languages
Russian (ru)
Inventor
Йоунг Сик Чунг
Соо Ах Парк
Рее Сун Ким
Сунг Ил Ким
Дзае Хиеон Дзун
Донг Киу Ким
Йоо Рин Ким
Хее Донг Парк
Сеонг Дзае Парк
Сунг Хак Ли
Дзу Хиун Ким
Мин Йоунг Дзунг
Original Assignee
Эл Джи Лайф Сайенсиз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эл Джи Лайф Сайенсиз Лтд. filed Critical Эл Джи Лайф Сайенсиз Лтд.
Publication of EA201390844A1 publication Critical patent/EA201390844A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей в качестве активных компонентов гидрохлорид лерканидипина и валсартан, и способу ее получения. Фармацевтическая композиция, содержащая гидрохлорид лерканидипина и валсартан по настоящему изобретению, обладает превосходным действием в отношении предотвращения и лечения сердечно-сосудистых заболеваний и их комплексных заболеваний и уменьшает неблагоприятные воздействия каждого компонента. Кроме того, настоящая композиция содержит гидрохлорид лерканидипина и валсартан в раздельной форме так, что увеличивает скорости растворения обоих компонентов и снижает неблагоприятные воздействия.The present invention relates to a pharmaceutical composition containing lercanidipine hydrochloride and valsartan as active components, and a method for its preparation. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan of the present invention has an excellent effect on the prevention and treatment of cardiovascular diseases and their complex diseases and reduces the adverse effects of each component. In addition, the present composition contains lercanidipine hydrochloride and valsartan in separate form so that increases the dissolution rate of both components and reduces adverse effects.

EA201390844A 2010-12-09 2011-12-07 COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION EA201390844A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
EA201390844A1 true EA201390844A1 (en) 2013-11-29

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390844A EA201390844A1 (en) 2010-12-09 2011-12-07 COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION

Country Status (17)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
WO2014142521A1 (en) * 2013-03-12 2014-09-18 주식회사 엘지생명과학 Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
MXPA06006118A (en) * 2003-12-01 2006-08-11 Lifecycle Pharma As Pharmaceutical compositions comprising lercanidipine.
WO2007001067A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.

Also Published As

Publication number Publication date
BR112013013415A2 (en) 2019-09-24
AR084195A1 (en) 2013-04-24
DOP2013000115A (en) 2014-07-31
CL2013001626A1 (en) 2013-10-04
EP2648730A2 (en) 2013-10-16
KR20120089787A (en) 2012-08-13
PE20140699A1 (en) 2014-06-13
UY33772A (en) 2012-07-31
CN103249415A (en) 2013-08-14
UA108277C2 (en) 2015-04-10
SG190326A1 (en) 2013-06-28
IL226449A0 (en) 2013-07-31
WO2012077968A3 (en) 2012-07-26
AU2011339150B2 (en) 2015-09-10
EP2648730A4 (en) 2014-08-06
CO6721030A2 (en) 2013-07-31
WO2012077968A2 (en) 2012-06-14
CN103249415B (en) 2017-12-12
AU2011339150A1 (en) 2013-06-06
KR101414814B1 (en) 2014-07-21
MX2013005716A (en) 2013-06-12

Similar Documents

Publication Publication Date Title
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
UA109991C2 (en) CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
UA109650C2 (en) BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS
EA201101192A1 (en) PHARMACEUTICAL COMPOSITION, INCLUDING DERIVATIVES GLUCOPIRANZYDHYPHENILMETHANE, PHARMACEUTICAL DOSED FORM, CONTAINING INDICATED DERIVATIVES, METHOD OF THEIR RECEIVING APPLICATIONS
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EA201491028A8 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
MX340985B (en) N-heteroaryl compounds.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
EA201591507A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY LACHINIMODOM
MX2015000179A (en) Itraconazole compositions and dosage forms, and methods of using the same.
EA201390844A1 (en) COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION
WO2013062442A3 (en) Composition for the treatment of multiple sclerosis (variants)
EA201590474A1 (en) PHARMACEUTICAL COMPOSITION BASED ON COMPOSITE CAPSULES INCLUDING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
MX2014014579A (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
MX365021B (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient.